NEW YORK (GenomeWeb News) – Norwegian diagnostics developer DiaGenic said today that it has signed up SRL Ranbaxy to market its genomic breast cancer test in India.
 
SRL Ranbaxy is a clinical reference pathology lab network with 40 labs and around 750 collection centers in India.
 
DiaGenic said it conducted a study of its blood-based gene expression test in India that showed it was not affected by variations in ethnicity or by the menopausal state of the patient.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.